Similar articles for PMID: 28668865

Year	Number of Results
2012	2
2013	3
2014	15
2015	21
2016	15
2017	6
2018	2
2019	2
2020	3
2021	4
2022	1
2024	0

1

Combining Abiraterone and Radiotherapy in Prostate Cancer Patients Who Progressed During Abiraterone Therapy.

Detti B, D'Angelillo RM, Ingrosso G, Olmetto E, Francolini G, Triggiani L, Bruni A, Borghesi S, Fondelli S, Carfagno T, Santini R, Santoni R, Trodella LE, Livi L. Detti B, et al. Anticancer Res. 2017 Jul;37(7):3717-3722. doi: 10.21873/anticanres.11744. Anticancer Res. 2017. PMID: 28668865

2

A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.

Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN. Azad AA, et al. Prostate. 2014 Nov;74(15):1544-50. doi: 10.1002/pros.22872. Epub 2014 Aug 29. Prostate. 2014. PMID: 25175831

3

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.

Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES. Maughan BL, et al. Prostate. 2015 Nov;75(15):1814-20. doi: 10.1002/pros.23064. Epub 2015 Aug 26. Prostate. 2015. PMID: 26306637

4

Line of abiraterone acetate in castration-resistant metastatic prostate cancer--Does it matter? report of a multi-institutional experience.

Gunduz S, Bozcuk H, Yıldız M, Goksu SS, Uysal M, Arslan D, Tatlı AM, Mutlu H, Coşkun HS, Ozdogan M. Gunduz S, et al. Indian J Cancer. 2015 Oct-Dec;52(4):658-60. doi: 10.4103/0019-509X.178379. Indian J Cancer. 2015. PMID: 26960509 Free article.

5

Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.

Conteduca V, Caffo O, Derosa L, Veccia A, Petracci E, Chiuri VE, Santoni M, Santini D, Fratino L, Maines F, Testoni S, De Giorgi U. Conteduca V, et al. Prostate. 2015 Sep;75(12):1329-38. doi: 10.1002/pros.23014. Epub 2015 May 15. Prostate. 2015. PMID: 25982919

6

A prospective study examining elder-relevant outcomes in older adults with prostate cancer undergoing treatment with chemotherapy or abiraterone.

Manokumar T, Aziz S, Breunis H, Rizvi SF, Joshua AM, Tannock IF, Alibhai SM. Manokumar T, et al. J Geriatr Oncol. 2016 Mar;7(2):81-9. doi: 10.1016/j.jgo.2016.01.003. Epub 2016 Feb 4. J Geriatr Oncol. 2016. PMID: 26853769

7

Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.

Sternberg CN, Castellano D, Daugaard G, Géczi L, Hotte SJ, Mainwaring PN, Saad F, Souza C, Tay MH, Garrido JM, Galli L, Londhe A, De Porre P, Goon B, Lee E, McGowan T, Naini V, Todd MB, Molina A, George DJ; Abiraterone Global EAP Investigators. Sternberg CN, et al. Lancet Oncol. 2014 Oct;15(11):1263-8. doi: 10.1016/S1470-2045(14)70417-6. Epub 2014 Sep 18. Lancet Oncol. 2014. PMID: 25242048 Clinical Trial.

8

Cytoreductive radiotherapy combined with abiraterone in metastatic castration-resistance prostate cancer: a single center experience.

Liu Y, Long W, Zhang Z, Mai L, Huang S, Liu B, Cao W, Wu J, Zhou F, Li Y, He L. Liu Y, et al. Radiat Oncol. 2021 Jan 6;16(1):5. doi: 10.1186/s13014-020-01732-y. Radiat Oncol. 2021. PMID: 33407637 Free PMC article.

9

CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.

Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H. Wissing MD, et al. Int J Cancer. 2015 Mar 15;136(6):E760-72. doi: 10.1002/ijc.29231. Epub 2014 Oct 3. Int J Cancer. 2015. PMID: 25242736

10

Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.

Wang Y, Zhang H, Shen W, He P, Zhou Z. Wang Y, et al. J Cancer Res Clin Oncol. 2018 Sep;144(9):1751-1768. doi: 10.1007/s00432-018-2664-y. Epub 2018 May 24. J Cancer Res Clin Oncol. 2018. PMID: 29797220 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

63 results

Results by year